Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Credentis AG maintains a focused patent presence with 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This prosecution activity is confined to a single distinct art unit, which indicates a narrow technical scope for the company's current intellectual property efforts. The involvement of 1 distinct examiner means that all current regulatory feedback is centralized through a single channel. This concentration allows the applicant to focus all resources on a specific set of examiner concerns without the distraction of multiple filings.
The busiest examiner, JAUHARI, SACHI, is responsible for the pending office action. This represents the total volume of pending actions for Credentis AG, placing the immediate outcome of their patent strategy in the hands of this specific official. Practitioners must align their arguments with the specific examination trends prevalent in the single art unit to ensure a favorable result. There are no other active matters to create conflicting priorities or require different technical arguments at this time.
With only a single pending office action, the administrative overhead for tracking multiple deadlines is minimal. The strategy for Credentis AG is currently defined by its interaction with JAUHARI, SACHI, making it essential to understand this examiner's past history within the Biotechnology & Pharmaceuticals field. This concentrated workload allows for a dedicated focus on resolving the single outstanding matter. Success in the distinct art unit will be the primary indicator of the company's current patenting progress in the life sciences sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JAUHARI, SACHI | 1 | 60.0% | +80.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18464817 | Dental Care Products Comprising Stannous Flouride | JAUHARI, SACHI | 26d |
| Art Unit | Apps |
|---|---|
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18464817 | Dental Care Products Comprising Stannous Flouride | JAUHARI, SACHI | 1654 | §103 | Final Rejection | 26d | Pending | Sep 11, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial